Hunan Fangsheng Pharmaceutical Co., Ltd.

Equities

603998

CNE100001VG6

Pharmaceuticals

End-of-day quote Shanghai S.E. 18:00:00 2024-06-24 EDT 5-day change 1st Jan Change
10.12 CNY -0.78% Intraday chart for Hunan Fangsheng Pharmaceutical Co., Ltd. -7.41% -7.66%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Fangsheng Pharma's Factories Pass GMP Inspection MT
Fangsheng Pharma Gets 12.1 Million Yuan in Government Grants in January-March MT
Fangsheng Pharma Withdraws Drug Registration Application For Headache Treatment MT
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Fangsheng Pharma's Drugs Placed in 2022 Chinese Drug Catalogue MT
Hunan Fangsheng Pharmaceutical Sees Up to 357% Surge in 2022 Profit; Shares Jump 3% MT
Hunan Fangsheng Pharma Unit to Resume Work After Leakage Forces Suspension MT
Hunan Fangsheng Pharmaceutical's Chinese Medicine Extraction Line Passes Regulatory Inspection MT
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Hunan Fangsheng Pharmaceutical Co., Ltd. announced that it expects to receive CNY 269.999999 million in funding CI
Hunan Fangsheng Pharmaceutical Co., Ltd. announced a financing transaction CI
Hunan Fangsheng Ruixin Pharmaceutical Co., Ltd. announced that it expects to receive CNY 160 million in funding from Hunan Fangsheng Pharmaceutical Co., Ltd., Changsha Xingchen Kangrui Venture Capital Partnership Enterprise (Limited Partnership), and another investor CI
China shares end lower as rising local COVID-19 cases drag consumer firms RE
Guo Jianjun agree to acquire 50% stake in Hunan Hengxing Pharmaceutical Technology Co., Ltd. from Hunan Fangsheng Pharmaceutical Co., Ltd. for CNY 9.4 million. CI
Yunnan Fuya Biotechnology Co., Ltd. announced that it expects to receive CNY 80 million in funding from Hunan Fangsheng Pharmaceutical Co., Ltd., Hong Kong TongSheng Industrial Co., Ltd. CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Hunan Fangsheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Hunan Fangsheng Pharmaceutical Co., Ltd. agreed to acquire Jiangxi Tengwangge Pharmaceutical Co., Ltd from Hunan Fangsheng Pharmaceutical Co., Ltd., Hunan Yuanhuixuan Management Consulting Co., Ltd and Guangzhou Changyixing Investment Management Co., Ltd for CNY CI
He Ye entered into share transfer agreement to acquire 51% stake in Yingkou Sanhua Pharmaceutical Co., Ltd. from Hunan Fangsheng Pharmaceutical Co., Ltd. for CNY 24 million CI
Chart Hunan Fangsheng Pharmaceutical Co., Ltd.
More charts
Hunan Fangsheng Pharmaceutical Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company primarily operates its businesses through two segments. The Pharmaceutical Manufacturing Business segment mainly provides cardiovascular and cerebrovascular drugs, orthopedic drugs, respiratory drugs, pediatric drugs, gynecological drugs and anti-infective drugs. The Company's main products include Xuesetong dispersible tablets, Xuesetong tablets, Garcinia bone-strengthening tablets, Dieda Huoxue capsules, Lysine Vitamin B12 granules, Cefuroxime tablets, Jinying capsules, Pudilan anti-inflammatory tablets, Xiaoer Jingxing cough granules, Ezetimibe tablets, Xuanqi bone-strengthening tablets, Qiangli Loquat Paste (honey-refined), Qiangli Loquat Dew and others. The Others segment is mainly engaged in other businesses such as medical services, pharmaceutical commerce and drug sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.12 CNY
Average target price
14.85 CNY
Spread / Average Target
+46.74%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 603998 Stock
  4. News Hunan Fangsheng Pharmaceutical Co., Ltd.
  5. Hunan Fangsheng Pharmaceutical's Chinese Medicine Extraction Line Passes Regulatory Inspection